A Warning Letter (WL) is a formal FDA enforcement communication identifying significant violations of regulatory requirements.
Warning letters can arise from deficiencies in informed consent, safety reporting, protocol compliance, data integrity, or quality system failures. Recipients are expected to respond promptly with root cause analysis, corrective actions, and evidence-based preventive measures. Warning letters can delay development timelines, increase oversight scrutiny, and affect sponsor and site reputations. Effective remediation and sustained compliance improvements are critical to resolving FDA concerns and preventing escalation.